Skip to main content

Quinja Disease Interactions

There are 4 disease interactions with Quinja (aloe polysaccharides / iodoquinol topical).

Moderate

Iodoquinol topical (applies to Quinja) hepatic dysfunction

Moderate Potential Hazard, Low plausibility. Applicable conditions: Liver Disease

Percutaneous absorption of iodoquinol topical has not been characterized, however, other 8-hydroxyquinoline derivatives (clioquinol, chlorquinaldol) are systemically absorbed following topical application. The use of oral iodoquinol therapy is contraindicated in patients with hepatic disease.

References

  1. (2001) "Product Information. Yodoxin (iodoquinol)." Glenwood Inc
Moderate

Iodoquinol topical (applies to Quinja) thyroid dysfunction

Moderate Potential Hazard, Low plausibility. Applicable conditions: Hypothyroidism, Hyperthyroidism

Percutaneous absorption of iodoquinol topical has not been characterized, however, other 8-hydroxyquinoline derivatives (clioquinol, chlorquinaldol) are systemically absorbed following topical application. The following thyroid abnormalities may occur during oral iodoquinol therapy: protein-bound serum iodine levels may be increased during treatment with iodoquinol resulting in alteration of certain thyroid function tests. Therapy with iodoquinol should be administered cautiously to patients with thyroid disease.

References

  1. (2001) "Product Information. Yodoxin (iodoquinol)." Glenwood Inc
Moderate

Iodoquinol topical (applies to Quinja) visual field defects

Moderate Potential Hazard, Low plausibility. Applicable conditions: Visual Defect/Disturbance

Percutaneous absorption of iodoquinol topical has not been characterized. However, other 8-hydroxyquinoline derivatives (clioquinol, chlorquinaldol) are systemically absorbed following topical application. The following visual field defects have occurred during oral iodoquinol therapy: optic neuritis and optic atrophy when given in high dosages for prolonged periods. Optic atrophy has been reported mostly in children treated for acrodermatitis enteropathica at daily dosages between 1300 to 3600 mg for up to two years. Visual deterioration may be irreversible. Therapy with iodoquinol should be administered cautiously in patients with or predisposed to visual defects. Some clinicians also recommend not using iodoquinol and related agents in pediatric patients under 12 years of age. Long-term therapy should be avoided in all patients.

References

  1. Behrens MM (1974) "Letter: Optic atrophy in children after diiodohydroxyquin therapy." JAMA, 228, p. 693-4
  2. Oakley GP Jr (1973) "The neurotoxicity of the halogenated hydroxyquinolines. A commentary." JAMA, 225, p. 395-7
  3. Idriss ZH (1975) "Letter: Diiodohydroxyquin and optic atrophy." Pediatrics, 55, p. 299
  4. Fleisher DI, Hepler RS, Landau JW (1974) "Blindness during diiodohydroxyquin (Diodoquin) therapy: a case report." Pediatrics, 54, p. 106-8
  5. Pittman FE, Westphal MC (1974) "Optic atrophy following treatment with diiodohydroxyquin." Pediatrics, 54, p. 81-3
  6. (2001) "Product Information. Yodoxin (iodoquinol)." Glenwood Inc
View all 6 references
Moderate

Iodoquinol topical- peripheral neuropathy

Moderate Potential Hazard, Low plausibility.

Percutaneous absorption of iodoquinol topical has not been characterized, however, other 8-hydroxyquinoline derivatives (clioquinol, chlorquinaldol) are systemically absorbed following topical application. Peripheral neuropathies may occur during oral iodoquinol therapy. Therapy with iodoquinol topical should be administered cautiously in patients with peripheral neuropathy.

References

  1. Oakley GP Jr (1973) "The neurotoxicity of the halogenated hydroxyquinolines. A commentary." JAMA, 225, p. 395-7
  2. (1974) "Warning on diiodohydroxyquin." Med Lett Drugs Ther, 16, p. 71-2
  3. American Academy of Pediatrics Committtee on Drugs (1990) "Clioquinol (iodochlorhydroxyquin, vioform) and iodoquinol (diiodohydroxyquin): blindness and neuropathy." Pediatrics, 86, p. 797-8
  4. Committee on Drugs (1974) "Blindness and neuropathy from diiodohydroxyquin-like drugs." Pediatrics, 54, p. 378-9
  5. (2001) "Product Information. Yodoxin (iodoquinol)." Glenwood Inc
View all 5 references

Quinja drug interactions

There is 1 drug interaction with Quinja (aloe polysaccharides / iodoquinol topical).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer